Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × Sarcoma, Ewing × Temozolomide × Clear all

Phase

Status

Sponsor Class

OTHER 12 INDUSTRY 7 NIH 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Central Nervous System Neoplasms 25 Glioblastoma 14 Astrocytoma 14 Oligodendroglioma 12 Gliosarcoma 12 Brain Neoplasms 11 Glioma 10 Ependymoma 4 Spinal Cord Neoplasms 3 Neuroblastoma 3 Somatostatinoma 2 Neoplasm Metastasis 2 Melanoma 2 Lymphoma 2 Lung Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Adenoma, Islet Cell 2 Sarcoma, Ewing 1 Neurotoxicity Syndromes 1 Neuroectodermal Tumors, Primitive 1 Medulloblastoma 1 Insulinoma 1 Glucagonoma 1 Glioma, Subependymal 1 Gastrointestinal Stromal Tumors 1 Gastrinoma 1 Ganglioneuroblastoma 1 Carcinoma, Neuroendocrine 1 Carcinoma, Islet Cell 1 Biliary Tract Neoplasms 1

Interventions

Vincristine 3 Ifosfamide 3 Etoposide 3 Doxorubicin 3 Cyclophosphamide 3 Surgical Procedures, Operative 2 Specimen Handling 2 Radiotherapy 2 Melphalan 2 Irinotecan 2 Busulfan 2 regorafenib 1 irinotecan sucrosofate 1 X-Rays 1 Trabectedin 1 Temozolomide 1 Radiation 1 Phantoms, Imaging 1 Magnetic Resonance Spectroscopy 1 Fluorodeoxyglucose F18 1 Dactinomycin 1 Bone Density 1 Biopsy 1 Absorptiometry, Photon 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02727387 2022-09-19

EW-2

Italian Sarcoma Group

Phase 2 Completed

Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon ⚡